Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROOPS: trabectedin plus olaparib in platinum-resistant advanced ovarian cancer
2018-000230-35Phase 2Completed
- Sponsor
- Fondazione del Piemonte per l'Oncologia
- Start
- Jun 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin and olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Fondazione del Piemonte per l'Oncologia. Primary endpoint: Progression-free survival rate at 4 months. Started Jun 2021; status: completed.
02
Drugs
trabectedinolaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2018-000230-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000230-35.